Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Lancet (London, England)|November 10, 2018
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trialEmil C Reisinger, Roland Tschismarov, Eckhard Beubler, et al.The Lancet. Infectious Diseases|March 6, 2015
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trialKatrin Ramsauer, Michael Schwameis, Christa Firbas, et al.Vaccine|June 8, 2013
A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virusSamantha Brandler, Claude Ruffié, Chantal Combredet, et al.Vaccine|January 24, 2007
A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitisArthur Lyons, Niranjan Kanesa-thasan, Robert A Kuschner, et al.Gastroenterology|May 13, 2008
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41Christoph S Klade, Heiner Wedemeyer, Thomas Berg, et al.Lancet (London, England)|March 19, 2023
Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trialRoland Tschismarov, Pierre Van Damme, Clara Germain, et al.Vaccine|June 30, 2009
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis CHeiner Wedemeyer, Elisabeth Schuller, Verena Schlaphoff, et al.Journal of Virology|July 1, 2026
Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigenVishaka Tiwarekar, Aileen Ebenig, Yvonne Predota, et al.Pageof 2